Granulomatosis with Polyangiitis Treatment Market Report and Forecast 2024-2032

Granulomatosis with Polyangiitis Treatment Market Size

The granulomatosis with polyangiitis treatment market is expected to grow at a CAGR of 4.90% during the forecast period of 2024-2032, driven by increased clinical trials and research to develop novel therapies and improve existing treatment options, enhanced disease recognition and management, and growing regulatory support across the 8 major markets. 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Granulomatosis with Polyangiitis Treatment Market Outlook

• The incidence of granulomatosis with polyangiitis tends to increase with age, with a peak incidence in older adults occurring between the ages of 64 to 75 years. Thus, the growing aging population is expected to drive market demand for effective treatments.

• One of the major market trends is the surge in clinical research activities aimed at improving existing treatment protocols.

• The market share is influenced by the growing regulatory support. Incentives offered by the health regulatory bodies encourage pharmaceutical companies to invest in rare disease treatments including granulomatosis with polyangiitis.

Granulomatosis with Polyangiitis Treatment Market Overview

Granulomatosis with polyangiitis is a medical condition that causes inflammation of blood vessels. The body parts affected by this disease include ears, nose, and kidney, among others. This disease is prevalent among children, adults, and geriatrics and causes severe symptoms such as chest pain, tiredness, nosebleeds, loss of appetite, and weight loss.

The granulomatosis with polyangiitis treatment market is witnessing an increase in the research and development activities by major biopharmaceutical companies. Key market players are actively investing in developing effective therapeutics to counter this disorder which is likely to lead to improved medications. Moreover, the market is anticipated to be aided by advanced X-rays, CT scans, and MRI in modern hospitals which is bolstering the diagnosis process for timely treatment of this condition. Furthermore, the market is likely to be navigated by the increasing geriatric population, coupled with the favorable reimbursement policies of the government.

Granulomatosis with Polyangiitis Treatment Market Growth Drivers

Increasing Elderly Population to Affect the Market Landscape Significantly

The prevalence of this rare vasculitis affecting small vessels is estimated between 1/6,400 - 42,000 with the incidence ranging between 1/84,000-475,000 every year. Recent data reveals that childhood-onset disease shows female predominance whereas a slight male predominance characterizes adult-onset. Among the anti-neutrophil-cytoplasmic-antibody (ANCA) associated vasculitides (AAV), granulomatosis with polyangiitis is considered as the most common type. The incidence rate is reported to be higher in adults compared to the pediatric age group with a peak incidence at 64 to 75 years of age. Since the prevalence of this autoimmune disease tends to increase with age, the growing aging population is expected to influence the market demand for effective treatments.

Growth in Clinical Trials to Meet Rising Granulomatosis with Polyangiitis Treatment Market Demand

There is a growing number of clinical trials and research activities focused on exploring new treatment strategies and drug combinations to manage granulomatosis with polyangiitis. For instance, a study published in JAMA Network Open suggested that granulomatosis with polyangiitis patients, if treated with rituximab compared to cyclophosphamide for induction therapy, are more likely to show achievement of remission. Such findings are set to influence clinical decision-making and guidelines associated with the choice of remission-inducing regimen for patients with GPA. Thus, the surge in clinical research activities is anticipated to improve existing treatment protocols and augment market demand in the forecast period.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Granulomatosis with Polyangiitis Treatment Market Trends

The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:

Granulomatosis with Polyangiitis Treatment Segmentation

Market Breakup by Drug Type
 

• Steroids
  • Prednisolone
  • Dexamethasone
  • Others

• Immunosuppressant
  • Cyclosporine
  • Tacrolimus
  • Sirolimus
  • Others

• Others

Market Breakup by Route of Administration

• Oral

• Injectable

• Others

Market Breakup by Mode of Purchase

• Prescription

• Over the Counter

Market Breakup by Gender

• Male

• Female

Market Breakup by End User

• Hospitals

• Specialty Clinics

• Home Healthcare

• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

• India

Granulomatosis with Polyangiitis Treatment Market Share

Market Segmentation Based on Drug Type is Anticipated to Witness Substantial Growth

Based on the drug type, the market is segmented into steroids (prednisolone, dexamethasone, and others) and immunosuppressants (cyclosporine, tacrolimus, sirolimus), among others. Immunosuppressants for the treatment of granulomatosis with polyangiitis are gaining traction in the healthcare industry, owing to the high response rate of this medication. Immunosuppressants such as cyclophosphamide with prednisone are widely used in the treatment of this disease as they pose a lesser chance of fatality during the treatment.

Such immunosuppressants are consumed orally which is a major advantage of this medication amidst the changing patient preference towards minimally invasive treatment procedures. Methotrexate and azathioprine are some other examples of immunosuppressants that calm down the immune system of the body, thereby, keeping the disease under control. Therefore, the anticipated increase in the demand for immunosuppressants are likely to aid the segment’s growth in the coming years.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Granulomatosis with Polyangiitis Treatment Market Analysis by Region

The segmentation based on the region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. Countries such as the United States are high healthcare spenders globally. The regulations of the government encouraging the development of therapeutics and diffusing knowledge about this disorder are propelling the market growth. In addition to this, the growing FDA approvals of immunosuppressants and drugs are further expanding the opportunities for this treatment market.

Leading Players in the Granulomatosis with Polyangiitis Treatment Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Genentech, Inc. (A subsidiary of F. Hoffman-La Roche Ltd)

This American biotechnology corporation, operating as an independent subsidiary under its parent organization Roche Holding AG, is one of the leading market players. Its FDA-approved Rituxan® (rituximab)  is commonly used to adult patients with granulomatosis with polyangiitis.

GlaxoSmithKline plc.

Global biopharma company GlaxoSmithKline plc. significantly contributes the granulomatosis with polyangiitis treatment market growth by investing heavily in R&D to bring new treatments for autoimmune diseases to market.

Teva Pharmaceutical Industries Ltd.

Israeli multinational pharmaceutical company Teva Pharmaceutical Industries Ltd. has a prominent presence in the market and is known for its TRUXIMA® (rituximab-abbs) injection, a biosimilar of Rituxan® (rituximab), for the treatment of granulomatosis with polyangiitis.

Pfizer Inc.

This global biopharmaceutical company is engaged in the development of innovative treatments for several autoimmune diseases. The key product of the company includes RUXIENCE®  (rituximab-pvvr) injection which is indicated for granulomatosis with polyangiitis in adult patients in combination with glucocorticoids.

Other key players in the market include Actiza Pharma, Sun Pharmaceutical Industries Ltd., Janssen Pharmaceutical, Inc., Novartis AG, and Sanofi.

Key Highlights of the Report

Key Questions Answered in the Granulomatosis with Polyangiitis Treatment Market Report

• What was the granulomatosis with polyangiitis treatment market value in 2023?
• What is the granulomatosis with polyangiitis treatment market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on drug type?
• What is the market breakup based on the route of administration?
• What is the market breakup by mode of purchase?
• What is the market breakup based on gender?
• Who are the major end users in the market?
• What are the major distribution channels present in the market?
• What are the major factors aiding the granulomatosis with polyangiitis treatment market demand? 
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is projected to witness expedited growth during the forecast period? 
• How does the prevalence and incidence of granulomatosis with polyangiitis affect the market landscape?
• What are the major granulomatosis with polyangiitis treatment market trends?
• Which drug type will dominate the market share? 
• Which route of administration is expected to have a high market value in the coming years?
• Which mode of purchase will experience the elevated demand in the market segment?
• Which gender is poised to fuel the market demand?
• Which end user is projected to contribute to the highest market growth?
• Which distribution channel is anticipated to boost the market share?
• Who are the key players involved in the granulomatosis with polyangiitis treatment market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?